Table 1 Baseline characteristics of stage 1 and stage 2 UK Biobank cohorts
Trait | Stage 1 | Stage 2 | ||
|---|---|---|---|---|
Cases (N = 7098) | Controls (N = 36,578) | Cases (N = 17,280) | Controls (N = 115,562) | |
Age at recruitment, years | 56 (8.09) | 56.9 (7.89) | 55.9 (8.23) | 56.7 (8.02) |
Female | 4199 (59.2) | 19,561 (53.5) | 10,197 (59.0) | 63,424 (54.9) |
Male | 2899 (40.8) | 17,017 (46.5) | 7083 (41.0) | 52,138 (45.1) |
FEV1, % predicted | 85.7 (16.6) | 94.0 (14.3) | 88.2 (15.3) | 94.2 (14.1) |
FEV1/FVC | 0.733 (0.0778) | 0.769 (0.0551) | 0.741 (0.0709) | 0.769 (0.0555) |
Ever smoker | 3093 (43.6) | 16,055 (43.9) | 7590 (43.9) | 50,413 (43.6) |
Never smoker | 3901 (55.0) | 20,002 (54.7) | 9357 (54.1) | 63,253 (54.7) |
Unknown | 104 (1.5) | 521 (1.4) | 333 (1.9) | 1896 (1.6) |
Hayfever, rhinitis or eczema status: | ||||
Yes | 3483 (49.1) | 8228 (22.5) | 7727 (44.7) | 23,269 (20.1) |
No | 3615 (50.9) | 28,350 (77.5) | 9553 (55.3) | 92,293 (79.9) |